Sareum Hldgs Plc (SAR) - Stock Price & Dividends
Exchange: London Exchange • Country: United Kingdom • Currency: GBX • Type: Common Stock • ISIN: GB00BMC3RJ87
Sareum Holdings plc is a clinical stage biotech company focused on developing innovative therapeutic drugs for cancer and autoimmune diseases.
The company leverages its proprietary Sareum Kinase Inhibitor Library drug discovery platform to design and develop small molecule therapeutic drugs. This platform enables the identification of novel kinase inhibitors that can be used to treat a range of diseases.
Sareum's lead product, SDC-1801, is a TYK2/JAK1 inhibitor currently in Phase 1a clinical trials for the treatment of autoimmune diseases. This drug candidate has the potential to address significant unmet medical needs in this area.
In addition to SDC-1801, the company is also advancing SDC-1802, another TYK2/JAK1 inhibitor, which is in preclinical development for cancer and cancer-immunotherapy applications. This drug candidate has shown promise in targeting specific molecular mechanisms involved in cancer development and progression.
Sareum is also developing SRA737, a clinical-stage, oral, selective Checkpoint kinase 1 (Chk1) inhibitor. This drug candidate has completed Phase II clinical trials and has shown potential in targeting cancer cell replication and DNA damage repair mechanisms.
Founded in 2004, Sareum Holdings plc is headquartered in Cambridge, the United Kingdom, a hub for biotech innovation. For more information, please visit the company's website at https://www.sareum.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
SAR Stock Overview
| Market Cap in USD | 35m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC SubIndustry | Pharmaceuticals |
| TER | 0.00% |
| IPO / Inception | 2004-10-11 |
SAR Stock Ratings
| Growth 5y | -0.60 |
| Fundamental | -68.8 |
| Dividend | - |
| Rel. Performance vs Sector | -13.95 |
| Analysts | - |
| Fair Price Momentum | 27.00 GBX |
| Fair Price DCF | - |
SAR Dividends
| Yield 12m | 0.00% |
| Yield on Cost 5y | 0.00% |
| Dividends CAGR 5y | 0.00% |
| Payout Consistency | 0.0% |
SAR Growth Ratios
| Growth 12m | -71.78% |
| Growth Correlation 12m | -87% |
| Growth Correlation 3m | -11% |
| CAGR 5y | 2.02% |
| CAGR/Mean DD 5y | 0.04 |
| Sharpe Ratio 12m | -0.67 |
| Alpha vs SP500 12m | -91.97 |
| Beta vs SP500 5y weekly | 0.65 |
| ValueRay RSI | 89.30 |
| Volatility GJR Garch 1y | 205.21% |
| Price / SMA 50 | 48.15% |
| Price / SMA 200 | -36.87% |
| Current Volume | 1007.5k |
| Average Volume 20d | 2104k |
External Links for SAR Stock
As of May 19, 2024, the stock is trading at GBX 34.00 with a total of 1,007,474 shares traded.
Over the past week, the price has changed by +17.24%, over one month by +65.85%, over three months by +4.62% and over the past year by -72.24%.
According to ValueRays Forecast Model, SAR Sareum Hldgs Plc will be worth about 29.8 in May 2025. The stock is currently trading at 34.00. This means that the stock has a potential downside of -12.26%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 176 | 418 |
| Analysts Target Price | - | - |
| ValueRay Target Price | 29.8 | -12.3 |